<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Liu Waller | Activity</title>
	<link>https://www.catswannabecats.com/members/colonypowder8/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/colonypowder8/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Liu Waller.</description>
	<lastBuildDate>Mon, 06 Jul 2026 08:03:58 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">48f0e50d71ab2011017171adaf4be645</guid>
				<title>Liu Waller posted an update: Local recurrence remains a challenging and common problem [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/22113/</link>
				<pubDate>Sat, 07 Jun 2025 08:09:59 -0400</pubDate>

									<content:encoded><![CDATA[<p>Local recurrence remains a challenging and common problem following curettage and joint-sparing surgery for giant cell tumour of bone (GCTB). <a href="https://www.selleckchem.com/products/protokylol-hydrochloride.html" rel="nofollow ugc">Protokylol price</a> We previously reported a 15% local recurrence rate at a median follow-up of 30 months in 20 patients with high-risk GCTB treated with neoadjuvant Denosumab. The aim of this study was to&hellip;<span class="activity-read-more" id="activity-read-more-22113"><a href="https://www.catswannabecats.com/activity/p/22113/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">05c9f18fb3f7894e5fdbacfe1152d13d</guid>
				<title>Liu Waller posted an update: vestigate whether these markers of subclinical [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/17657/</link>
				<pubDate>Tue, 03 Jun 2025 07:58:51 -0400</pubDate>

									<content:encoded><![CDATA[<p>vestigate whether these markers of subclinical cardiovascular disease can be modified to reduce the risk of cardiovascular disease in CKD.</p>
<p>In CKD, increases in NT-proBNP were significantly associated with greater risk of incident HF and AF, and increases in sST2 were associated with HF. Further studies should investigate whether these markers&hellip;<span class="activity-read-more" id="activity-read-more-17657"><a href="https://www.catswannabecats.com/activity/p/17657/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a5cc34cda9b9316e656e72fb5d68952e</guid>
				<title>Liu Waller posted an update: A novel pH-sensitive colorimetric film was prepared based on [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/10240/</link>
				<pubDate>Sun, 01 Jun 2025 00:07:06 -0400</pubDate>

									<content:encoded><![CDATA[<p>A novel pH-sensitive colorimetric film was prepared based on immobilizing red barberry anthocyanins (RBAs) within composite chitin nanofiber (CNF) and methylcellulose (MC) matrices. The incorporation of CNFs and RBAs improved their mechanical properties, moisture resistance, and UV-vis screening properties. Moreover, the RBAs could be used as&hellip;<span class="activity-read-more" id="activity-read-more-10240"><a href="https://www.catswannabecats.com/activity/p/10240/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">caa4f7611045bf25c8f84b8ebdbae866</guid>
				<title>Liu Waller became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/10186/</link>
				<pubDate>Sat, 31 May 2025 23:59:45 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>